Wen Jiang
9 Papers
12 Citations
Wen Jiang is an academic researcher. The author has contributed to research in topics: Neutralizing antibody & Medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Jinchao Zhang,Shuo Chen,Xun Gui,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor is reported.
Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination
Li-Jun Duan,Wen Jiang,Zhuang Wang,Lin Yao,Ka-Li Zhu,Q. Meng,Baoming Wang,Li-Bo Li,Guo-Lin Wang,Mai-Juan Ma +9 more
TL;DR: In this paper , the authors examined the neutralization activity of sera collected from previously SARS-CoV-2-infected individuals and naive individuals who received BBIBP-CorV or CoronaVac to BA.1 and the earlier variants Alpha, Beta, and Delta.
10
An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Shuo Chen,Xun Gui,Jinchao Zhang,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, is reported showing high SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor by introducing the LALA mutation to the Fc region (MW05/LALA).
7
Presence of anti-nuclear antibody associated with worse clinical outcomes of anti-NMDAR encephalitis
TL;DR: ANA was prevalent in patients with anti-NMDAR encephalitis, and associated with a worse prognosis and impaired neurological recovery, and with a better clinical outcome at 12 months after the disease onset.
Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage
Wen Jiang,Zhe-Rui Zhang,Yuhe Zhu,Ben Chen,Chunying Gu,Zhiyan Liu,Xukai Zhang,Hualong Xiong,Ya-Nan Zhang,Bin Zheng,Rongjuan Wang,Shasha Jiao,An Wang,Jinchao Zhang,Shuang Wang,Bo Zhang,Gang Li,Xun Gui +17 more
TL;DR: Data support the development of MW3321 as a monotherapy or cocktail against SARS-CoV-2-related diseases and could effectively reduce viral burden in hACE2-transgenic mice challenged with either wild-type or Delta Sars-Cov-2 strains through viral neutralization and Fc-mediated effector functions.